Identification

Name
Furosemide
Accession Number
DB00695  (APRD00608, DB07799)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]

Structure
Thumb
Synonyms
  • 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
  • 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
  • 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
  • 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
  • Frusemide
  • Furosemid
  • Furosemida
  • Furosemide
  • Furosemidu
  • Furosemidum
  • Lasix (tn)
External IDs
LB-502 / NSC-269420
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Furosemide Tab 20mgTablet20 mgOralApotex Corporation1977-12-31Not applicableCanada
Apo Furosemide Tab 40mgTablet40 mgOralApotex Corporation1976-12-31Not applicableCanada
Apo Furosemide Tab 80mgTablet80 mgOralApotex Corporation1986-12-31Not applicableCanada
FuosemideTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-10Not applicableUs
FurosemideTablet40 mg/1OralMylan Institutional1995-10-01Not applicableUs
FurosemideTablet20 mg/1OralNucare Pharmaceuticals,inc.1981-10-19Not applicableUs
FurosemideTablet40 mg/1OralGolden State Medical Supply Inc.1983-11-10Not applicableUs
FurosemideTablet40 mg/1OralA-S Medication Solutions1981-08-27Not applicableUs50090 232320180913 8702 rgpxyk
FurosemideTablet20 mg/1OralRemedy Repack2012-07-192013-08-24Us00172 2908 60 nlmimage10 bc26de56
FurosemideTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-10Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-furosemideTablet40 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemideTablet20 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemideTablet80 mgOralAvanstra Inc2011-08-112014-08-21Canada
Bio-furosemideTablet40 mgOralBiomed Pharma2003-04-11Not applicableCanada
Bio-furosemideTablet20 mgOralBiomed Pharma2003-04-11Not applicableCanada
Dom-furosemideTablet20 mgOralBiomed Pharma2003-10-142013-08-02Canada
Dom-furosemideTablet40 mgOralBiomed Pharma2003-10-142013-08-02Canada
FurosemideTablet40 mg/1OralRemedy Repack2015-04-292017-03-20Us00603 3740 21 nlmimage10 59242c81
FurosemideSolution40 mg/4mLOralPrecision Dose, Inc.2009-06-082014-03-31Us
FurosemideTablet80 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2004-10-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Active-Medicated specimen collection kitFurosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)KitN.O.R.T.H., Inc.2013-10-31Not applicableUs
Diascreen 12-Panel Medicated Collection SystemFurosemide (20 mg/1) + Benzalkonium chloride (0.13 g/100g)KitIt3 Medical Llc2016-07-27Not applicableUs
Diuscreen Medicated Collection KitFurosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)KitMaveron Health, LLC.2015-06-012016-10-28Us
Diuscreen Multi-Drug Medicated Test KitFurosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)KitMaveron Health, LLC.2015-06-012016-10-28Us
Rx-Specimen Collection KitFurosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)KitMas Management Group Inc.2015-07-23Not applicableUs
TOXYCOLOGY Medicated Collection SystemFurosemide (20 mg/1) + Benzalkonium chloride (0.13 g/100g)KitIt3 Medical Llc2016-07-27Not applicableUs
Urinx Medicated Specimen CollectionFurosemide (20 mg/1) + Benzalkonium chloride (0.0013 g/1mL)KitPharmaco Technology Llc2015-06-012015-12-31Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FurosemideFurosemide (40 mg/5mL)SolutionOralUNSPECIFIED2007-03-31Not applicableUs
FurosemideFurosemide (20 mg/1)TabletOralWatson Labs2007-05-28Not applicableUs
FurosemideFurosemide (80 mg/1)TabletOralVintage Pharmaceuticals, LLC2007-09-132007-09-13Us
FurosemideFurosemide (10 mg/1mL)Injection, solutionIntramuscular; IntravenousHospira, Inc.2006-07-312006-07-31Us
FurosemideFurosemide (20 mg/1)TabletOralRemedy Repack2010-11-012011-02-10Us
FurosemideFurosemide (80 mg/1)TabletOralWatson Labs2007-05-28Not applicableUs0591 030220180818 17235 1higyu7
FurosemideFurosemide (40 mg/1)TabletOralVintage Pharmaceuticals, LLC2007-09-132007-09-13Us
FurosemideFurosemide (10 mg/1mL)Injection, solutionIntramuscular; IntravenousHospira, Inc.2006-07-312006-07-31Us
FurosemideFurosemide (40 mg/1)TabletOralWatson Labs2007-05-28Not applicableUs
FurosemideFurosemide (20 mg/1)TabletOralVintage Pharmaceuticals, LLC2007-09-132007-09-13Us
International/Other Brands
Diurapid (Mibe Jena) / Diurin (Mylan) / Diurmessel (Biomep) / Eutensin (Sanofi) / Frumex / Frusenex / Frusol (Rosemont) / Furo-Puren (Actavis) / Seguril (Sanofi)
Categories
UNII
7LXU5N7ZO5
CAS number
54-31-9
Weight
Average: 330.744
Monoisotopic: 330.007719869
Chemical Formula
C12H11ClN2O5S
InChI Key
ZZUFCTLCJUWOSV-UHFFFAOYSA-N
InChI
InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
IUPAC Name
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.

Associated Conditions
Pharmacodynamics

Furosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome.

Mechanism of action

Furosemide, a loop diuretic, inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
UCarbonic anhydrase 2Not AvailableHuman
Absorption

60% absorbed in patients with normal renal function

Volume of distribution
Not Available
Protein binding

95% bound to plasma proteins

Metabolism

Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.

Route of elimination

Furosemide is excreted in urine. Significantly more furosemide is excreted in urine following the I.V. injection than after the tablet or oral solution.

Half life

2 hours

Clearance
Not Available
Toxicity

Profound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Furosemide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be increased when used in combination with Furosemide.
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Furosemide.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Furosemide.
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Furosemide.
AbediterolThe risk or severity of hyperkalemia can be increased when Abediterol is combined with Furosemide.
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Furosemide.
AcebutololThe risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol.
AceclofenacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Aceclofenac.
AcemetacinFurosemide may increase the excretion rate of Acemetacin which could result in a lower serum level and potentially a reduction in efficacy.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Furosemide.
Food Interactions
  • Avoid alcohol.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Increase potassium intake; add a banana or orange juice; unless instructed otherwise.
  • Take with food to reduce irritation.

References

Synthesis Reference

Angelo Signor, Alfredo Guerrato, Giovanni Signor, "Process for the preparation of furosemide." U.S. Patent US5739361, issued June, 1971.

US5739361
General References
  1. Rais-Bahrami K, Majd M, Veszelovszky E, Short BL: Use of furosemide and hearing loss in neonatal intensive care survivors. Am J Perinatol. 2004 Aug;21(6):329-32. [PubMed:15311369]
  2. Korpi ER, Kuner T, Seeburg PH, Luddens H: Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Mol Pharmacol. 1995 Feb;47(2):283-9. [PubMed:7870036]
  3. Tia S, Wang JF, Kotchabhakdi N, Vicini S: Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit. J Neurosci. 1996 Jun 1;16(11):3630-40. [PubMed:8642407]
  4. Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ: Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Mol Pharmacol. 1996 Sep;50(3):670-8. [PubMed:8794909]
External Links
Human Metabolome Database
HMDB0001933
KEGG Drug
D00331
KEGG Compound
C07017
PubChem Compound
3440
PubChem Substance
46506779
ChemSpider
3322
BindingDB
25902
ChEBI
47426
ChEMBL
CHEMBL35
Therapeutic Targets Database
DAP000043
PharmGKB
PA449719
HET
FUN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Furosemide
ATC Codes
C03EB01 — Furosemide and potassium-sparing agentsC03CB01 — Furosemide and potassiumG01AE10 — Combinations of sulfonamidesC03CA01 — Furosemide
AHFS Codes
  • 40:28.08 — Loop Diuretics
PDB Entries
1z9y / 2xn5 / 3rf4
FDA label
Download (462 KB)
MSDS
Download (74.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentAcute Kidney Injury (AKI)1
0RecruitingPreventionTransfusion-associated Circulatory Overload1
1CompletedBasic ScienceDrug Drug Interactions1
1CompletedBasic ScienceDyspnea1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of Ipragliflozin1
1CompletedBasic ScienceRenal Hemodynamics1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentAcute Heart Failure (AHF)1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentRenal Failure1
1CompletedTreatmentType 2 Diabetes Mellitus1
1Not Yet RecruitingBasic ScienceMedication Absorption1
1Not Yet RecruitingTreatmentBody Weight Changes1
1RecruitingTreatmentCongestive Heart Failure (CHF) / Prophylaxis of cardiomyopathy1
1RecruitingTreatmentDifficulty Breathing1
1TerminatedTreatmentHeart Failure, Unspecified / Impaired Renal Function1
1, 2Active Not RecruitingBasic ScienceDyspnea / Healthy Volunteers1
1, 2CompletedSupportive CareDyspnea1
1, 2CompletedTreatmentHeart Failure, Unspecified1
1, 2CompletedTreatmentHeart Failure, Unspecified / Renal Function Abnormal1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2WithdrawnTreatmentAcute Decompensated Heart Failure (ADHF)1
2CompletedSupportive CarePulmonary Complications1
2CompletedTreatmentAscites / Liver Cirrhosis1
2CompletedTreatmentBronchiolitis1
2CompletedTreatmentCutaneous Warts1
2CompletedTreatmentHeart Failure, Unspecified1
2CompletedTreatmentTransient Tachypnoea of the Newborn1
2RecruitingOtherChronic Lung Disease of Prematurity1
2RecruitingPreventionHigh Blood Pressure (Hypertension)1
2RecruitingPreventionHypertension, Pregnancy-Induced1
2RecruitingTreatmentAcute Heart Failure (AHF) / Decompensated Heart Failure1
2RecruitingTreatmentPolyps, Nasal1
2WithdrawnTreatmentDelayed Graft Function1
2, 3CompletedTreatmentCongestive Heart Failure (CHF)1
2, 3CompletedTreatmentHeart Failure, Unspecified2
2, 3RecruitingHealth Services ResearchAcute Heart Failure (AHF)1
2, 3TerminatedTreatmentAcute Renal Failure (ARF)1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedSupportive CareBronchiolitis1
3CompletedTreatmentCongestive Heart Failure (CHF) / Impaired Renal Function1
3CompletedTreatmentCutaneous Common Warts1
3CompletedTreatmentFluid Overload1
3CompletedTreatmentHypertension,Essential / Impaired Renal Function1
3CompletedTreatmentTransient Tachypnea of the Newborn1
3CompletedTreatmentChronic heart failure with reduced ejection fraction (NYHA Class III) / Chronic heart failure with reduced ejection fraction (NYHA Class IV)1
3Not Yet RecruitingTreatmentAcute Myocardial Infarction With Right Ventricular Extension1
3RecruitingDiagnosticChronic Kidney Disease (CKD)1
3RecruitingTreatmentFluid Balance of ICU Patients / Fluid Overload1
3RecruitingTreatmentHeart Failure, Unspecified2
3SuspendedTreatmentCongestive Heart Failure (CHF)1
3TerminatedTreatmentCritically Ill / Renal Failure1
3Unknown StatusPreventionContrast Induced Nephropathy (CIN)1
3Unknown StatusTreatmentChronic Lung Diseases1
3WithdrawnTreatmentHeart Failure, Unspecified1
3WithdrawnTreatmentRenal Function Disorder1
4CompletedPreventionArterial Hypotension / Congestive Heart Failure (CHF) / Edema / High Blood Pressure (Hypertension)1
4CompletedTreatmentAcute Decompensated Heart Failure (ADHF)1
4CompletedTreatmentAcute Heart Failure (AHF)1
4CompletedTreatmentAscites / Liver Cirrhosis2
4CompletedTreatmentChronic Heart Failure (CHF) / Congestive Heart Failure (CHF)1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4CompletedTreatmentColorectal Disorders1
4CompletedTreatmentCongestive Heart Failure (CHF)2
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
4CompletedTreatmentEdema / Glomerulonephritis minimal lesion1
4CompletedTreatmentHeart Failure, Diastolic1
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentPreeclampsia1
4CompletedTreatmentStable Chronic Heart Failure2
4Not Yet RecruitingOtherCystoscopy1
4Not Yet RecruitingTreatmentAcute Heart Failure (AHF)1
4RecruitingDiagnosticEnd Stage Renal Disease (ESRD)1
4RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentHypertension Resistant To Conventional Therapy1
4RecruitingTreatmentProteinuria / Renal Insufficiency,Chronic1
4RecruitingTreatmentPulmonary Embolism (PE)1
4TerminatedTreatmentAcute Decompensated Heart Failure (ADHF)1
4TerminatedTreatmentAcute Kidney Injury (AKI) / Critical Illness / Fluid Overload1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentAcute Heart Failure (AHF)1
4Unknown StatusTreatmentDiuresis Preserved / Hemodialysis Treatment / Kidney Insufficiency, Chronic1
4Unknown StatusTreatmentHealthy Male and Female Volunteers1
4WithdrawnTreatmentAcute Renal Failure (ARF)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedDiagnosticCardiorenal Syndrome1
Not AvailableCompletedDiagnosticChronic Kidney Disease (CKD)1
Not AvailableCompletedPreventionAcute Renal Failure (ARF)1
Not AvailableCompletedTreatmentAcromegaly1
Not AvailableCompletedTreatmentAcute Kidney Injury (AKI)1
Not AvailableCompletedTreatmentFluid Over-load1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableCompletedTreatmentRenal Stones1
Not AvailableNot Yet RecruitingTreatmentHeart Decompensation1
Not AvailableRecruitingNot AvailableAcidosis, Renal Tubular / Calcium Nephrolithiasis / Vacuolar Proton-Translocating ATPases1
Not AvailableRecruitingDiagnosticAcute Renal Failure (ARF)1
Not AvailableRecruitingDiagnosticCritical Illness / Oliguria1
Not AvailableRecruitingDiagnosticDelayed Graft Function / Kidney Function / Kidney Transplant; Complications1
Not AvailableRecruitingPreventionChronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary1
Not AvailableRecruitingTreatmentCritical Care / Fluid Shifts1
Not AvailableRecruitingTreatmentHeart Failure, Unspecified1
Not AvailableTerminatedDiagnosticAcute Decompensated Heart Failure (ADHF)1
Not AvailableTerminatedTreatmentAcute Decompensated Heart Failure (ADHF) / Cardiac Failure / Heart Failure, Unspecified1
Not AvailableTerminatedTreatmentBrain Swelling / Dehydration1
Not AvailableTerminatedTreatmentObesity-induced Hyperfiltration1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableUnknown StatusTreatmentHypernatremia / Respiratory Failure / Volume Overload1
Not AvailableUnknown StatusTreatmentIntra-Abdominal Hypertension1
Not AvailableWithdrawnPreventionRenal Impairment After Cardiac Surgery1
Not AvailableWithdrawnTreatmentAnemia Treatment Among Patients Suffering From Left Ventricular Systolic Dysfunction1
Not AvailableWithdrawnTreatmentCongestive Heart Failure (CHF)2
Not AvailableWithdrawnTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Organon usa inc
  • Smith and nephew solopak div smith and nephew
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Wockhardt ltd
  • Wyeth ayerst laboratories
  • Sanofi aventis us llc
  • Roxane laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Dava pharmaceuticals inc
  • Excellium pharmaceutical inc
  • International medication systems ltd
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kalapharm inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Superpharm corp
  • Vintage pharmaceuticals inc
  • County line pharmaceuticals llc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • American Regent
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Cardinal Health
  • Central Texas Community Health Centers
  • Comprehensive Consultant Services Inc.
  • Coupler Enterprises Inc.
  • CVS Pharmacy
  • DAVA Pharmaceuticals
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Excellium Pharmaceutical Inc.
  • General Injectables and Vaccines Inc.
  • Goldline Laboratories Inc.
  • Group Health Cooperative
  • H and H Laboratories
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Intervet International
  • Ipca Laboratories Ltd.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Luitpold Pharmaceuticals Inc.
  • Macnary Ltd.
  • Major Pharmaceuticals
  • Mason Distributors
  • Mckesson Corp.
  • Medvantx Inc.
  • Merrell Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neighborcare Repackaging Inc.
  • Neuman Distributors Inc.
  • Norwich Pharmaceuticals Inc.
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Sandoz
  • Sanofi-Aventis Inc.
  • Southwood Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Stat Scripts LLC
  • Talbert Medical Management Corp.
  • Taylor Pharmaceuticals
  • Tya Pharmaceuticals
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Vatring Pharmaceuticals
  • Vedco Inc.
  • Vintage Pharmaceuticals Inc.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
Kit
TabletOral20 mg
TabletOral40 mg
InjectionIntramuscular; Intravascular10 mg/1mL
InjectionIntramuscular; Intravenous10 mg/1mL
InjectionIntramuscular; Intravenous10 mg/2mL
InjectionIntramuscular; Intravenous100 mg/10mL
InjectionIntramuscular; Intravenous20 mg/2mL
InjectionIntramuscular; Intravenous40 mg/4mL
InjectionIntravenous10 mg/1mL
Injection, solutionIntramuscular; Intravenous10 mg/1mL
Injection, solutionIntravenous10 mg/1mL
SolutionOral10 mg/1mL
SolutionOral40 mg/5mL
SolutionOral40 mg/4mL
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
LiquidIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous20 mg
SolutionIntravenous250 mg
LiquidIntravenous250 mg
SolutionIntravenous10 mg
TabletOral80 mg
LiquidOral10 mg
SolutionOral10 mg
LiquidIntramuscular; Intravenous20 mg
TabletOral500 mg
LiquidIntravenous10 mg
KitOral
Prices
Unit descriptionCostUnit
Hydro 40 40% Foam 150 gm Can182.52USD can
Hydro 40 40% Foam 70 gm Can148.99USD can
Furosemide 10 mg/ml Solution 60ml Bottle17.99USD bottle
Furosemide 10 mg/ml Solution 120ml Bottle15.98USD bottle
Furosemide powder3.51USD g
Lasix Special 500 mg Tablet3.25USD tablet
Urex 1 gm tablet2.47USD tablet
Furosemide 10 mg/ml cartrg1.45USD ml
Lasix 80 mg tablet1.0USD tablet
Furosemide 10 mg/ml Solution0.9USD ml
Furosemide 10 mg/ml0.75USD ml
Lasix 40 mg tablet0.53USD tablet
Furosemide 80 mg tablet0.45USD tablet
Lasix 20 mg tablet0.42USD tablet
Lasix 10 mg/ml Solution0.3USD ml
CVS Pharmacy diuretic 50 mg softgel0.17USD softgel capsule
Furosemide 40 mg tablet0.16USD tablet
Furosemide 20 mg tablet0.14USD tablet
Apo-Furosemide 80 mg Tablet0.13USD tablet
Novo-Semide 80 mg Tablet0.13USD tablet
Nat herbal diuretic tablet sa0.1USD tablet
Apo-Furosemide 40 mg Tablet0.07USD tablet
Natural herbal diuretic tablet0.07USD tablet
Novo-Semide 40 mg Tablet0.07USD tablet
Apo-Furosemide 20 mg Tablet0.05USD tablet
Novo-Semide 20 mg Tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)206U.S. Patent 3,058,882.
water solubility73.1 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.03SANGSTER (1993)
logS-3.66ADME Research, USCD
Caco2 permeability-6.5ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.118 mg/mLALOGPS
logP2.71ALOGPS
logP1.75ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.25ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area122.63 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity77.47 m3·mol-1ChemAxon
Polarizability30.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier-0.8833
Caco-2 permeable-0.6436
P-glycoprotein substrateNon-substrate0.8775
P-glycoprotein inhibitor INon-inhibitor0.9272
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.924
CYP450 2C9 substrateNon-substrate0.6878
CYP450 2D6 substrateNon-substrate0.8351
CYP450 3A4 substrateNon-substrate0.6789
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9602
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6885
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6469
BiodegradationNot ready biodegradable0.9881
Rat acute toxicity2.1362 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9342
hERG inhibition (predictor II)Non-inhibitor0.8525
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-03dr-0090000000-da505a3f09285d049f34
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-0f89-2190000000-53c91100e89c81f0fa30
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-01ox-9660000000-83d8486cbca0dd3487c9
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-f3a3dcb92cfcdff9f7dc
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0019000000-946089b12d2ab6fd05a4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-04af1dec204d462d4bc4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1090000000-1af70d23e1a0ebaa0878
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9770000000-0c5cd578b5b69a1a61d4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9800000000-3303b20f9b23e24ae312
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9400000000-23cfec716ac8fbcb092f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0019000000-e73aa1d969ab4255732b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-33053544119c01ac6b45
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1090000000-7029ab63efa73a3ff88d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9670000000-4bad8928bbcfc85f431f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9800000000-2193e38e314f2b18be26
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9600000000-e703f7ab6221182df156
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-f3645e993869ff3886ba
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-18400153a811f7100a2f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0f79-0090000000-7e491b92dab050fb81c0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-8e41d38fe799d96230a6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-cfec4a54171c58245919
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0ug0-0193000000-b55039ca13cbc3acd9a8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0290000000-1f1017fe4370d9541f6d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-9110000000-505f1e781d384073f688
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001j-9000000000-cd886e0521fb4d1bdc82
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8a69e99643ee37bc1883
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-f7ac3c9eea39ed725cfc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8a294fd51a34073aa4a1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-b16e204dec9ae7938d40
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f8a-9220000000-3bde836fe7e67c9b8755
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-9025c2261c96ca3aa551
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8d05f828403d0fe7cac4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-3cd4f8015eb5fafacacb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-34937031271e62c39c1f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-40e9966d335f71aedb96
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0290000000-586707fb0116e8b61643
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-9000000000-f6727b05eb8ee02a6e7c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-51662bec1d461d0f0a5a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-8eea44e0dd27bb59939d
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Aminobenzenesulfonamides
Alternative Parents
4-halobenzoic acids / Aminobenzoic acids / Halobenzoic acids / Benzenesulfonyl compounds / Benzoic acids / Aniline and substituted anilines / Benzoyl derivatives / Phenylalkylamines / Secondary alkylarylamines / Chlorobenzenes
show 15 more
Substituents
Aminobenzenesulfonamide / 4-halobenzoic acid or derivatives / Aminobenzoic acid / Aminobenzoic acid or derivatives / Halobenzoic acid or derivatives / 4-halobenzoic acid / Halobenzoic acid / Benzenesulfonyl group / Benzoic acid / Benzoic acid or derivatives
show 37 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, furans, chlorobenzoic acid (CHEBI:47426)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Brater DC: Pharmacology of diuretics. Am J Med Sci. 2000 Jan;319(1):38-50. [PubMed:10653443]
  2. Davies DL, Wilson GM: Diuretics: mechanism of action and clinical application. Drugs. 1975;9(3):178-226. [PubMed:1092541]
  3. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name
PGD
Uniprot ID
P52209
Uniprot Name
6-phosphogluconate dehydrogenase, decarboxylating
Molecular Weight
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kim GH, Na KY, Kim SY, Joo KW, Oh YK, Chae SW, Endou H, Han JS: Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Nephrol Dial Transplant. 2003 Aug;18(8):1505-11. [PubMed:12897087]
  2. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087]
  3. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961]
  4. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, a...
Gene Name
SLCO2A1
Uniprot ID
Q92959
Uniprot Name
Solute carrier organic anion transporter family member 2A1
Molecular Weight
70043.33 Da
References
  1. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [PubMed:7754369]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]

Drug created on June 13, 2005 07:24 / Updated on September 21, 2018 00:04